Vitti Long Haul

Vitti Long Haul is dedicated to advancing new therapies for people living with the lasting effects of COVID-19, with a focus on pulmonary fibrosis and long-haul symptoms. Our treatments, VL-PX10 and VL-P22, are developed from mesenchymal stem cells, exosomes, and biomaterials, and are currently in Phase 2 human clinical trials. For patients who may not qualify for trials, we also provide access through a physician-led Expanded Access Program. Operating under FDA guidelines and built on years of scientific research, Vitti Long Haul is committed to delivering safe, effective, and innovative care. Patients and physicians can connect with us to learn more about trial enrollment and advanced treatment options.